We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 01, 2021

Intravitreous Treatment of Severe Ocular VHL Disease With Ranibizumab + E10030

Clinical & Experimental Ophthalmology


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical & Experimental Ophthalmology
Intravitreous treatment of severe ocular von Hippel-Lindau disease using a combination of the VEGF inhibitor, ranibizumab, and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial
Clin Exp Ophthalmol 2021 Sep 21;[EPub Ahead of Print], CK Hwang, EY Chew, CA Cukras, TDL Keenan, WT Wong, WM Linehan, P Chittiboina, K Pacak, HE Wiley

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading